Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
作者信息
Kumar Naveen
机构信息
Department of Urology, Narayan Medical College and Hospital, Sasaram, Bihar, India.
出版信息
Indian J Urol. 2021 Oct-Dec;37(4):369-371. doi: 10.4103/iju.iju_288_21. Epub 2021 Oct 1.
Abstract
摘要
相似文献
1
Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?Checkmate 274试验：纳武利尤单抗会成为高危肌层浸润性尿路上皮癌辅助治疗的新标准吗？
Indian J Urol. 2021 Oct-Dec;37(4):369-371. doi: 10.4103/iju.iju_288_21. Epub 2021 Oct 1.
2
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.纳武利尤单抗单药治疗复发性转移性尿路上皮癌（CheckMate 032）：一项多中心、开放标签、两阶段、多臂1/2期试验。
Lancet Oncol. 2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X. Epub 2016 Oct 9.
3
[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].局部晚期或转移性尿路上皮癌的一线治疗：一项关于辅助性纳武单抗治疗与安慰剂对比治疗侵袭性高危尿路上皮癌患者的随机双盲III期多中心研究（CheckMate 274）-AUO的AB 58/17
Urologe A. 2017 Oct;56(10):1331-1332. doi: 10.1007/s00120-017-0480-7.
4
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌（CheckMate 141）：一项随机3期试验的健康相关生活质量结果
Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
5
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.纳武利尤单抗对比依维莫司用于晚期肾细胞癌患者：随机、开放标签、III 期 CheckMate 025 试验的长期随访更新结果。
Cancer. 2020 Sep 15;126(18):4156-4167. doi: 10.1002/cncr.33033. Epub 2020 Jul 16.
6
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.纳武利尤单抗对比多西他赛用于治疗既往接受过治疗的晚期非小细胞肺癌（CheckMate 017 和 CheckMate 057）：3 年更新结果及肝转移患者的结局。
Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.
7
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.纳武利尤单抗治疗铂类化疗后转移性尿路上皮癌（CheckMate 275）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.
8
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.纳武利尤单抗联合伊匹单抗的疗效根据 CheckMate 214 中 IMDC 风险因素的数量。
Eur Urol. 2020 Apr;77(4):449-453. doi: 10.1016/j.eururo.2019.10.025. Epub 2019 Nov 13.
9
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼治疗晚期肾细胞癌患者的患者报告结局（CheckMate 214）：一项随机、III 期试验。
Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15.
10
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.CheckMate 141 随机 3 期临床试验的亚组分析：纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌，超出 RECIST 定义的进展
Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.
引用本文的文献
1
Exploiting the Molecular Basis of Oesophageal Cancer for Targeted Therapies and Biomarkers for Drug Response: Guiding Clinical Decision-Making.利用食管癌的分子基础进行靶向治疗及药物反应生物标志物研究：指导临床决策
Biomedicines. 2022 Sep 22;10(10):2359. doi: 10.3390/biomedicines10102359.
本文引用的文献
1
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
2
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.阿替利珠单抗辅助治疗与观察用于肌层浸润性尿路上皮癌（IMvigor010）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12.
3
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南：2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
4
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.纳武利尤单抗治疗铂类化疗后转移性尿路上皮癌（CheckMate 275）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.
5
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.浸润性膀胱癌辅助化疗：2013 年更新的随机试验系统评价和荟萃分析。
Eur Urol. 2014 Jul;66(1):42-54. doi: 10.1016/j.eururo.2013.08.033. Epub 2013 Aug 28.
6
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.无疾病生存可作为上尿路上皮癌总生存的替代指标。
World J Urol. 2013 Feb;31(1):5-11. doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26.
7
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.无疾病生存 2 或 3 年与行根治性膀胱切除术的肌层浸润性膀胱癌患者的 5 年总生存相关。
J Urol. 2011 Feb;185(2):456-61. doi: 10.1016/j.juro.2010.09.110. Epub 2010 Dec 17.
Zotero 插件